Boston Sci Dives Deeper into Oncology with Intera Acquisition

Boston Scientific, a finalist for medtech company of the year, is expanding its offerings into the cancer treatment space with the acquisition of Intera Oncology. The Marlborough MA-based company would not disclose details of the deal other than it was expected to close in the first half of 2025.

The Newton, MA-based company has developed the Intera 3000 Hepatic Artery Infusion Pump and floxuridine,  a chemotherapy drug – both of which are approved by FDA. The Intera 3000 pump is used to administer hepatic artery infusion (HAI) therapy to treat tumors in the liver primarily caused by metastatic colorectal cancer.

The safety and effectiveness of the Intera 3000 pump are supported by data from randomized controlled trials demonstrating the clinical benefits of HAI therapy for patients with unresectable colorectal metastases to the liver, both before and following resection.

Data from these trials have highlighted that HAI therapy significantly improves tumor response, time to progression and overall survival compared to systemic chemotherapy, and that combining HAI with systemic chemotherapy may lead to extended survival and higher conversion-to-resection rates in both chemotherapy-naïve and previously treated patients.

Current Phase II and III studies are exploring HAI therapy use in larger patient groups for first-line, second-line, and post-surgery adjuvant treatments.

Related:H.B. Fuller Establishes European HQ with Acquisitions in Medical Adhesive Space

"Liver cancer is a leading cause of cancer-related death, and we are committed to providing meaningful solutions to safely and effectively treat various forms of this disease with minimal systemic side effects and improved outcomes for patients," said Peter Pattison, president, Interventional Oncology and Embolization, Boston Scientific. "Interest in HAI therapy has grown in the oncology community given improved techniques, positive clinical results and ongoing trials. We believe this acquisition will enable us to provide a more comprehensive set of solutions to physicians and their patients to treat both primary and metastatic forms of liver cancer."